trending Market Intelligence /marketintelligence/en/news-insights/trending/le2cmznpafsvuugzwd86hw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Kitov Pharma agrees to settle securities lawsuits for $2M

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Kitov Pharma agrees to settle securities lawsuits for $2M

Kitov Pharma Ltd. said it entered a settlement agreement regarding three shareholder class action lawsuits filed against the company.

The classes in all the lawsuits, which alleged violations of U.S. federal securities laws, will receive $2 million under the proposed settlement. The Israeli biopharmaceutical company expects its insurers to fund the settlement consideration, plus related expenses.

One lawsuit was filed in the District Court for the Southern District of New York while two were filed in the Superior Court for the State of California.

Under the proposed settlement, which will have no impact on the company's statement of operations, Kitov will not admit any wrongdoing or violation of federal or state securities laws.

The proposal is subject to certain conditions, including court approval.